Our #1 AI Stock Pick is on a steep discount - 29$ instead of 99$! Click here to access exclusive investment research and ad free browsing! Our #1 AI Stock Pick is on a steep discount - 29$ instead of 99$! Click here to access exclusive research! ClearBridge Investments, an investment management company, released its “ClearBridge SMID Cap Growth Strategy” second quarter 2023 investor letter. A copy of the same can be downloaded here. The strategy underperformed the Russell 2500 Growth Index in the second quarter. On an absolute basis, the strategy gained 10 sectors in which it was invested during the quarter. The industrials, health care, and energy sectors were the leading contributors while the consumer discretionary and consumer staples sectors detracted. Overall stock selection effects detracted from performance while sector allocation effects contributed on a relative basis. In addition, please check the fund’s top five holdings to know its best picks in 2023. ClearBridge SMID Cap Growth Strategy highlighted stocks like Karuna Therapeutics, Inc. (NASDAQ:KRTX) in the second quarter 2023 investor letter. Headquartered in Boston, Massachusetts, Karuna Therapeutics, Inc. (NASDAQ:KRTX) is a biopharmaceutical company. On September 21, 2023, Karuna Therapeutics, Inc. (NASDAQ:KRTX) stock closed at $168.15 per share. One-month return of Karuna Therapeutics, Inc. (NASDAQ:KRTX) was -4.74%, and its shares lost 25.64% of their value over the last 52 weeks. Karuna Therapeutics, Inc. (NASDAQ:KRTX) has a market capitalization of $6.334 billion. ClearBridge SMID Cap Growth Strategy made the following comment about Karuna Therapeutics, Inc. (NASDAQ:KRTX) in its Q2 2023 investor letter: “We initiated a new position in Karuna Therapeutics, Inc. (NASDAQ:KRTX), in the health care sector, a biopharmaceutical company which creates and delivers transformative medicines for people living with psychiatric and neurological conditions. The company is preparing to launch a drug focused on schizophrenia in the second half of 2024, which is generating excitement from the physician community as the majority of drugs utilize a dopamine-related mechanism for this indication, unlike Karuna’s. Karuna also has trials underway to expand this neurology drug into other psychiatric indications with large total addressable markets.” Copyright: dolgachov / 123RF Stock Photo Karuna Therapeutics, Inc. (NASDAQ:KRTX) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 42 hedge fund portfolios held Karuna Therapeutics, Inc. (NASDAQ:KRTX) at the end of second quarter which was 33 in the previous quarter. We discussed Karuna Therapeutics, Inc. (NASDAQ:KRTX) in another article and shared the list of best high risk high reward stocks to buy. In addition, please check out our hedge fund investor letters Q2 2023 page for more investor letters from hedge funds and other leading investors. Suggested Articles: Disclosure: None. This article is originally published at Insider Monkey. NASDAQ:KRTXYahoo FinanceDaily Newsletter Returns since its inception in May 2014 (through May 20, 2024) Warren Buffett Berkshire Hathaway $293,447,417,000 David Einhorn Greenlight Capital $1,491,303,000 George Soros Soros Fund Management $5,416,602,000 Jim Simons Renaissance Technologies $77,426,184,000 Leon Cooperman Omega Advisors $1,886,381,000 Carl Icahn Icahn Capital LP $22,521,664,000 Steve Cohen Point72 Asset Management $22,767,998,000 John Paulson Paulson & Co $3,510,256,000 David Tepper Appaloosa Management LP $4,198,712,000 Paul Tudor Jones Tudor Investment Corp $6,160,740,000                                                            Get our editor’s daily picks straight in your inbox! 